Conference call and webcast to be held at 4:30 p.m. ET Trevi Therapeutics, Inc.(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior […]

Lifecore Biomedical to Report Fourth Quarter and Fiscal Year 2025 Financial Results on August 7, 2025 Webcast Scheduled for Thursday, August 7 at 4:30 p.m. Eastern GlobeNewswire July 31, 2025 CHASKA, Minn., July 31, 2025 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced

Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration withFrenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason® genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to enhance the understanding of cardio-kidney-metabolic diseases

Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended June 27, 2025. https://mma.prnewswire.com/media/1008600/Envista_Logo.jpg “Envista achieved accelerated growth across all of our businesses and major geographies in the second quarter,” said Paul Keel, CEO. “This allowed us to further increase investments in growth, operations, and people, while also delivering strong improvement in year-over-year

A ParadiseAcquisition Corp. (Nasdaq: APADU) (the “Company”), a blank check company incorporated as a British Virgin Islands business company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses, today announced the closing of its previously announced initial public offering

— Generated Q2'25 total revenue, net of $1.36 billion and adjusted revenue of $1.34 billion. Adjusted revenue came in above the high end of our guidance range — Reported Q2'25 GAAP net income of $34 million and adjusted net income of $75 million — Delivered Q2'25 adjusted EBITDA of $172 million Rocket Companies, Inc. (NYSE:RKT)

Ramaco Resources, Inc. (NASDAQ: METC, METCB, METCL, METCZ) (“Ramaco Resources” or the “Company”) announced today the closing of its previously announced public offering (the “Offering”) of senior unsecured notes due 2030 (the “Notes”). The Notes will mature on July 31, 2030, unless redeemed prior to maturity. The Notes bear interest at a rate of 8.250%

Hub Group Reports Second Quarter 2025 Results GlobeNewswire July 31, 2025 Highlights: GAAP diluted earnings per share (EPS) of $0.42 for the second quarter Second quarter revenue of $905.6 million Non-GAAP adjusted EPS of $0.45, which excludes adjustments for vendor settlements in the quarter Operating income of $34 million or 3.8% of revenue, adjusted operating

— For the quarter, total revenues were $3.175 billion, towards the upper end of the guidance range; — GAAP diluted EPS was $9.06, at the upper end of the guidance range, and non-GAAP diluted EPS was $9.38, above the upper end of the guidance range; — Cash flow from operating activities for the quarter and

(NASDAQ:SGMO), RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) — Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025. The company will hold a conference call at 4:30 p.m. Eastern on